The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era

Ilana Zalcberg Renault, Vanesa Scholl, Rocio Hassan, Paola Capelleti, Marcos de Lima, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Tyrosine kinase inhibitors have changed the management and outcomes of chronic myeloid leukemia patients. Quantitative polymerase chain reaction is used to monitor molecular responses to tyrosine kinase inhibitors. Molecular monitoring represents the most sensitive tool to judge chronic myeloid leukemia disease course and allows early detection of relapse. Evidence of achieving molecular response is important for several reasons: 1. early molecular response is associated with major molecular response rates at 18-24 months; 2. patients achieving major molecular response are less likely to lose their complete cytogenetic response; 3. a durable, stable major molecular response is associated with increased progression-free survival. However, standardization of molecular techniques is still challenging.

Original languageEnglish (US)
Pages (from-to)455-460
Number of pages6
JournalRevista Brasileira de Hematologia e Hemoterapia
Volume33
Issue number6
DOIs
StatePublished - Dec 2011
Externally publishedYes

Keywords

  • BCR-ABL positive
  • Chronic
  • Cytogenetic
  • Leukemia
  • Monitoring
  • Mutation
  • Myelogenous
  • Polymerase chain reaction

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era'. Together they form a unique fingerprint.

  • Cite this